GLUCOPHAGE 500 mg Merck Serono
|
|
- Sharleen Todd
- 6 years ago
- Views:
Transcription
1 GLUCOPHAGE 500 mg Film-coated tablets Composition Film-coated tablets containing 500 mg of metformin (INN) hydrochloride (equivalent to 390 mg of metformin Excipients Polyvidone K 30, magnesium stearate, hypromellose, q.s. one film-coated tablet of 529 mg. Pharmaceutical form Film-coated tablet - Pack of 50 tablets = 25 g of metformin HCI per - Pack of 100 tablets = 50 g of metformin HCI per - Pack of 500 tablets = 250 g of metformin HCI per pack Pharmacotherapeutic category ORAL ANTIDIABETIC AGENT (A: gastrointestinal tract and metabolism). As an adjunct to adequate dietary management, Glucophage 500 mg is an oral antidiabetic agent (biguanide) intended for the treatment of adult-onset diabetes. In some cases, it may be used in association with insulin. Contraindications This drug MUST NOT BE USED in the following kidney function with increased levels of creatinine in the blood), - infectious diseases with high (respiratory tract infection, urinary tract infection), - persistent diarrhea, repeated vomiting, - before and for 2 days after a surgical procedure, - before or at the time of radiologic tests involving the use of intravascular iodinated contrast agents (for example, intravenous urography, angiogra- phy). The drug will be reinstituted only after renal function has been found to be normal, - severe destabilisation of diabetes (ketoacidosis), - heart failure, respiratory insufficiency, - hepatic insufficiency (impairment of liver function), - excessive intake of alcoholic beverages, - pregnancy and breast-feeding. Side Effects This drug can, in some people, cause more or less disagreeable effects. Gastrointestinal discomfort (nausea, vomiting, diarrhea) may occur at the beginning of treatment, especially if Glucophage 500 mg tablets are not taken with meals. These symptoms are usually temporary, lasting about 10 days, and can be reduced by taking the tablets during or at the end of meals. Should symptoms persist, stop taking the treatment and consult your doctor. ketoacidosis or lactic acidosis) requiring a specific treatment. If this occurs you should immediately stop taking Glucophage and consult your doctor promptly. REPORT ANY UNDESIRABLE OR DISTRESSING EFFECT WHICH HAS NOT BEEN MENTIONED IN THIS PACKAGE INSERT TO YOUR DOCTOR OR YOUR PHARMACIST. Warnings ketoacidosis or lactic acidosis) requiring a specific treatment. If this occurs, you should stop taking Glucophage immediately and consult your doctor promptly.
2 GLUCOPHAGE 500 mg - p.2/2 Precautions Your doctor will order periodic laboratory tests to determine the levels of creatinine in your blood in order to check your kidney function, which must be adequate since oral antidiabetic agents are substantially eliminated by the kidneys. Therefore, you should drink at least 1.5 liters of fluids every day. Certain illnesses or medications (corticosteroids oral contraceptives, some diuretics) may cause a more or less severe destabilisation of diabetes requiring temporary recourse to insulin therapy. You should inform your doctor of any other treatments you are receiving and of any infectious or viral illness such as flu, respiratory tract infection or urinary tract infection. If you are scheduled to undergo radiologic studies involving the use of iodinated contrast agents, such as intravenous urography or angiography, your doctor will ask you to stop the treatment with Glucophage prior to or at the time of the test and will only resume the treatment after making sure that your kidneys are functioning normally. If you are hospitalised for tests, a surgical procedure, or complications such as heart disease, tell your doctor that you are taking Glucophage. Avoid excessive intake of alcoholic beverages. IF IN DOUBT, DO NOT HESITATE TO SEEK THE ADVICE OF YOUR PHARMACIST OR YOUR DOCTOR. Pregnancy During pregnancy, the treatment of diabetes is based on insulin therapy. If you discover that you are pregnant while taking Glucophage, your treatment will be replaced by insulin. Inform your doctor so that he may make the necessary changes to your treatment. Inform your doctor if you wish to become pregnant. As a general rule, if you are pregnant or breastfeeding you should always ask your doctor for advice before taking a medication. Effect on Ability to Drive and Use Machines When used alone, Glucophage does not cause hypoglycemia. Therefore, there is no particular risk when driving or using machines. Intake or use of other medications Inform your doctor or your pharmacist if you are taking or have recently taken another drug, i.e. corticosteroids, anti hypertensive agents of the ACE inhibitor class (angiotensin-converting enzyme inhibitors), diuretics, ritodrine, salbutamol or terbutaline, iodized contrast media or medications containing alcohol, even if an over-the-counter medication is involved. Storage No special requirements for storage. Do not use after the expiry date shown on the outer packaging. Dosage and Administration The dosage of Glucophage 500 mg is determined by your doctor on an individual basis according to the results of laboratory blood glucose measurements. In general, the average dosage is 1 tablet one to three times a day. Method and route of administration This medication is administered by mouth. Oral route. Frequency and time at which the drug should be taken Swallow the tablets without chewing during or at the end of meals. For example, for a dosage of two tablets daily, take 1 tablet with breakfast and 1 tablet with dinner. IN ALL CASES PATIENTS SHOULD STRICTLY COMPLY WITH THEIR DOCTOR S PRESCRIPTION. Duration of treatment Glucophage must be taken daily without interruption, except if specifically directed by your doctor. If you have forgotten to take a Glucophage 500 mg film-coated tablet: Take the next dose at the usual time. Do not double the dose of Glucophage. Packaging t: 50, 100, 500.
3 GLUCOPHAGE 850 mg Pharmaceutical form: Glucophage 850 mg tablets are white, circular, convex and film-coated. Film-coated tablets containing 850 mg metformin (INN) hydrochloride (equivalent to 663 mg metformin As an adjunct to adequate diet and exercise Glucophage 850 mg is an oral Anti-diabetic agent (biguanide) intended for the treatment of type 2 diabetes. In adults, Glucophage 850 mg may be given alone or with oral anti-diabetic agents, or with insulin. In children from 10 years old and adolescents, Glucophage 850 mg may be given alone or with insulin. A reduction of diabetic complications has been shown in overweight type 2 diabetic adult patients treated with metformin as first-line therapy after diet therapy Dosage The dosage of Glucophage 850 mg is determined by your doctor on an individual basis according to the results of laboratory blood glucose measurement. The initial dosage is usually one tablet of Glucophage 850 mg once daily in children from 10 years old and adolescents and one tablet of Glucophage 850 mg 2 or 3 times daily in adults. The maximum recommended dose is 2 g daily in children and 3 g daily in adults (taken as 2 or 3 divided doses). In case of decreased renal function, the dosage should be adjusted based on renal function. Contra-indications This drug MUST NOT BE USED in the following - known hypersensitivity to metformin hydrochloride or any of the product ingredients, - severe destabilisation of diabetes (ketoacidosis or pre-coma), kidney function with increased blood creatinine levels or decreased creatinine clearance <60 ml/mn), - infectious diseases (for example respiratory tract infection, urinary tract infection), - following an X-ray examination involving the use of iodinated contrast media (for example intravenous urography, angiography), - disease which may cause tissue hypoxia (heart failure, recent myocardial infarction, respiratory insufficiency, shock), - hepatic insufficiency (impaired liver function), - persistent or severe diarrhoea, recurrent vomiting, - excessive consumption of alcoholic beverages, - during breast-feeding.
4 GLUCOPHAGE 1000 mg Film-coated tablets Composition Film-coated tablets containing 1000 mg of metformin (INN) hydrochloride (equivalent to 780 mg of metformin Excipients Polyvidone K 30, magnesium stearate, Opadry clear YS , q.s. one film-coated tablet of 1071 mg. Pharmaceutical form Film-coated tablets. - Pack of 30 tablets = 30 g of metformin HCI per pack - Pack of 60 tablets = 60 g of metformin HCI per Pharmacotherapeutic category ORAL ANTIDIABETIC AGENT (AlOBA02: gastrointestinal tract and metabolism). As an adjunct to adequate dietary management, Glucophage 1000 mg is an oral antidiabetic agent (biguanide) intended for the treatment of adult diabetes. In some cases, it may be used in association with insulin. Contraindications This drug MUST NEVER BE USED in the following - Known hypersensitivity to metformin hydrochloride or any of the product ingredients, - severe destabilisation of diabetes (ketoacidosis), kidney function with increased blood creatinine levels), - infectious diseases (respiratory tract infection, urinary tract infection), -during the two days following an X-ray examination involving the use of iodinated contrast media (for example, intravenous urography, angiography), - heart failure, respiratory insufficiency, - hepatic insufficiency (impaired liver function), - persistent diarrhea, recurrent vomiting, - excessive consumption of alcoholic beverages, - during breast-feeding. Side Effects As with all medications, Glucophage 1000 mg filmcoated tablets, can cause undesirable effects. Gastrointestinal discomfort (nausea, vomiting, diarrhea) may occur at the beginning of treatment, especially if Glucophage 1000 mg tablets are not taken with meals. These symptoms are generally transient, lasting about 10 days, and can be reduced by taking the tablets with or after meals. Should symptoms persist, stop taking the treatment and consult your doctor. Vomiting, abdominal pain accompanied by muscle cramps and/or a general feeling of malaise with severe fatigue occurring during therapy may be signs of serious destabilisation of your diabetes (diabetic ketoacidosis or lactic acidosis) requiring specific treatment. If this occurs you should stop taking Glucophage immediately and consult your doctor promptly. REPORT ANY UNDESIRABLE OR DISTRESSING EFFECT WHICH HAS NOT BEEN MENTIONED IN THIS PACKAGE INSERT TO YOUR DOCTOR OR PHARMACIST. Warnings ketoacidosis or lactic acidosis) requiring specific treatment. If this occurs, you should stop taking Glucophage immediately and consult your doctor promptly. Precautions Your doctor will prescribe periodic laboratory tests (to determine your blood creatinine levels) in order to check your kidney function, which must be ade-
5 GLUCOPHAGE 1000 mg - p.2/2 quate since oral antidiabetic agents are excreted mainly by the kidneys. Certain illnesses or medications (corticosteroids and certain diuretics, ritodrine, salbutamol, terbutaline and ACE inhibitors) may cause more or less severe destabilisation of diabetes. You should inform your doctor of any other treatment you are receiving and of any infectious illnesses such as influenza, respiratory tract infection or urinary tract infection. If you are scheduled to undergo X-ray examinations involving the use of iodized contrast media, such as intravenous urography or angiography, your doctor will ask you to discontinue treatment with Glucophage prior to or at the time of the test and will not resume treatment until 48 hours after the test, after ensuring that your kidneys are functioning normally. If you are hospitalised for tests, a surgical procedure, or for any other reason, advise your doctor that you are taking Glucophage. Avoid consumption of alcoholic beverages. Pregnancy During pregnancy, treatment of diabetes is based on insulin therapy. If you discover that you are pregnant while taking Glucophage, your treatment will be replaced by insulin. Inform your doctor so that he may make the necessary changes to your treatment. Inform your doctor if you wish to become pregnant. Breastfeeding This drug is contraindicated during breast-feeding. As a general rule, if you are pregnant or breastfeeding you should always ask your doctor for advice before taking a medication. Effect on Ability to Drive and Use Machines When used alone, Glucophage does not cause hypoglycemia. Consequently, there is no particular risk when driving or using machines. However, in association with other antidiabetic agents (sulphonylurea, hypoglycemic agents, insulin, repaglinide), it is important to be aware of the onset of hypoglycemia, and of its effects on concentration. Intake or use of other medications Inform your doctor or your pharmacist if you are taking or have recently taken another drug, i.e. corticosteroids, anti hypertensive agents of the ACE inhibitor class (angiotensin-converting enzyme inhibitors), diuretics, ritodrine, salbutamol or terbutaline, iodized contrast media or medications containing alcohol, even if an over-the-counter medication is involved. Storage No special requirements for storage. Do not use after the expiry date shown on the outer packaging. Dosage and Administration The dosage of Glucophage 1000 mg is determined by your doctor on an individual basis according to the results of laboratory blood glucose measurement. In general, the average dosage is 2 tablets per day (taken with or after meals). Method and route of administration Oral route. Frequency and time at which the drug should be taken. Swallow the tablets without chewing during or at the end of meals. For example, for a dosage of two tablets daily, take 1 tablet with breakfast and I tablet with your evening meal. IN ALL CASES PATIENTS SHOULD STRICTLY COMPLY WITH THEIR DOCTOR S PRESCRIPTION. Duration of treatment Glucophage must be taken daily without interruption, except if specifically indicated by your doctor. If you have forgotten to take a Glucophage 1000 mg filmcoated tablet: Take the next dose at the usual time. Do not double the dose of Glucophage 1000 mg filmcoated tablets. If you have taken more Glucophage 1000 mg film-coated tablets than indicated: Consult your doctor or pharmacist immediately. Packaging t: 30, 60.
Glucophage XR is contra-indicated during breast-feeding.
Name GLUCOPHAGE XR 1000 mg Prolonged release tablets Active ingredient Metformin hydrochloride Composition Each Glucophage XR 1000 mg prolonged release tablet contains as active ingredient 1000 mg metformin
More informationSIOFOR mg film-coated tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER SIOFOR 1000 1000mg film-coated tablets For use in children from 10 years and adults METFORMIN HYDROCHLORIDE This leaflet is a copy of the Summary of Product Characteristics
More informationPACKAGE LEAFLET: Information for the user. METFORMINE Film-coated tablets 500 mg, 850 mg or 1000 mg (Metformin hydrochloride)
PACKAGE LEAFLET: Information for the user METFORMINE Film-coated tablets 500 mg, 850 mg or 1000 mg (Metformin hydrochloride) Read this leaflet carefully before you start taking this medicine. - Keep this
More informationSIOFOR mg film-coated tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER SIOFOR 850 850mg film-coated tablets METFORMIN HYDROCHLORIDE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for
More informationMetformin Hydrochloride
Metformin Hydrochloride 500 mg, 850 mg, 500 mg LA and 750 mg LA Tablet Description Informet is a preparation of metformin hydrochloride that belongs to a biguanide class of oral antidiabetic drugs. Metformin
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Metformin HCl Bluefish 500 mg/ 850 mg/ 1000 mg, film-coated tablets metformin hydrochloride
PACKAGE LEAFLET: INFORMATION FOR THE USER Metformin HCl Bluefish 500 mg/ 850 mg/ 1000 mg, film-coated tablets metformin hydrochloride Read all of this leaflet carefully before you start taking this medicine
More informationCEDIAMATE Metformin Tablets USP 500 mg
CEDIAMATE Metformin Tablets USP 500 mg COMPOSITION: Cediamate Each un-coated tablet contains: Metformin Hydrochloride USP Excipients 500 mg Q.S PHARMACOLOGY: Pharmacotherapeutic group: Blood Glucose lowering
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Metformin HCl Mylan 500 mg/ 850 mg/ 1000 mg, film-coated tablets metformin hydrochloride
PACKAGE LEAFLET: INFORMATION FOR THE USER Metformin HCl Mylan 500 mg/ 850 mg/ 1000 mg, film-coated tablets metformin hydrochloride Read all of this leaflet carefully before you start taking this medicine.
More informationPackage leaflet: Information for the user. GLUCOPHAGE 500 mg powder for oral solution in sachets metformin hydrochloride
Package leaflet: Information for the user GLUCOPHAGE 500 mg powder for oral solution in sachets metformin hydrochloride Read all of this leaflet carefully before you start taking this medicine - Keep this
More informationPackage leaflet: Information for the patient. Metformin Teva 1000 mg Film-coated Tablets Metformin hydrochloride
Package leaflet: Information for the patient Metformin Teva 1000 mg Film-coated Tablets Metformin hydrochloride Read all of this leaflet carefully before you start taking this medicine because it contains
More informationPackage leaflet: Information for the patient. Metformin Actavis 500 mg and 850 mg filmcoated tablets. metformin hydrochloride
Package leaflet: Information for the patient Metformin Actavis 500 mg and 850 mg filmcoated tablets metformin hydrochloride Read all of this leaflet carefully before you start taking this medicine because
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Metformin HCl Bluefish 500 mg, film-coated tablets Metformin HCl Bluefish 850 mg, film-coated tablets Metformin HCl Bluefish 1000 mg,
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Bolamyn SR 500 mg Prolonged Release Tablets (metformin hydrochloride) Almus Bolamyn SR 500 mg Prolonged Release Tablets (metformin hydrochloride)
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Each film-coated tablet contains metformin hydrochloride 850 mg corresponding to mg of metformin.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Metformin 850 mg Film-coated Tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains metformin hydrochloride
More informationMETFORMIN HYDROCHLORIDE PROLONGED RELEASE TABLETS IP
For 0 the use only of a Registered Medical Practitioner or hospital or a laboratory This package insert is continually updated: Please read carefully before using a new pack METFORMIN HYDROCHLORIDE PROLONGED
More informationFor the use only of a Registered Medical Practitioner or a Hospital or a Laboratory. Metformin Hydrochloride Prolonged Release Tablets IP
For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory METLEAD TM 500 SR / METLEAD TM FORTE SR Metformin Hydrochloride Prolonged Release Tablets IP QUALITATIVE AND QUANTITATIVE
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) SUMMARY INFORMATION ON A REFERRAL OPINION FOLLOWING AN ARBITRATION
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit CPMP/4082/00 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) SUMMARY INFORMATION ON A REFERRAL OPINION FOLLOWING
More informationPage 1 of 9 SUMMARY OF PRODUCT CHARACTERISTICS
Page 1 of 9 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Glucophage SR 1000 mg prolonged release tablet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One prolonged release tablet contains
More informationCONTRAINDICATIONS: Hypersensitivity to the active substance or to any of the excipients
Galvus PRESENTATION: Each tablet contains 50 mg of Vildagliptin INDICATIONS: For the treatment of type 2 diabetes mellitus in adults: i) As monotherapy in patients inadequately controlled by diet and exercise
More informationPage 1 of 9 SUMMARY OF PRODUCT CHARACTERISTICS
Page 1 of 9 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Glucophage SR 750 mg prolonged release tablet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One prolonged release tablet contains
More informationEach film-coated tablet contains metformin hydrochloride 850 mg corresponding to metformin base 662,9 mg
SUMMARY OF THE PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Metformin Actavis 850 mg film-coated tablet. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains metformin
More informationSUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Metformin 500mg Tablets BP 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains Metformin Hydrochloride 500mg equivalent
More informationGLUCOPHAGE 500 mg mg mg
GLUCOPHAGE 500 mg - 750 mg - 1000 mg Prolonged release tablets metformin hydrochloride This medicine is intended for adult patients only Read all of this leaflet carefully before you start taking this
More informationPACKAGE LEAFLET DIASTABOL 50 MG TABLETS. Version 1.0 1
PACKAGE LEAFLET DIASTABOL 50 MG TABLETS 1 PACKAGE LEAFLET: INFORMATION FOR THE USER Diastabol 50 mg tablets miglitol Read all of this leaflet carefully before you start taking this medicine. - Keep this
More informationPackage leaflet: Information for the patient Komboglyze 2.5 mg/1,000 mg film-coated tablets saxagliptin/metformin
Package leaflet: Information for the patient Komboglyze 2.5 mg/1,000 mg film-coated tablets saxagliptin/metformin Read all of this leaflet carefully before you start taking this medicine because it contains
More informationConsumer Medicine Information. Metformin Generic Health. What is in this leaflet. Before you take Metformin Generic Health
Consumer Medicine Information Metformin Generic Health metformin hydrochloride 500 mg and 850 mg tablets What is in this leaflet Please read this leaflet carefully before you start using Metformin Generic
More informationGlucophage NAME OF THE MEDICINE DESCRIPTION PHARMACOLOGY PRODUCT INFORMATION. Metformin hydrochloride
Glucophage Metformin hydrochloride PRODUCT INFORMATION Life threatening lactic acidosis can occur due to accumulation of metformin. Risk factors include renal impairment, old age and the use of high doses
More informationsrmp DK/H/2377/ /DC Gliclazid Sigillata
srmp DK/H/2377/001-002/DC Gliclazid Sigillata VI.2 VI.2.1 Elements for a public summary Overview of disease epidemiology Diabetes is a disease which causes patients blood sugar levels to be high. Gliclazide
More informationPROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: Read this entire leaflet carefully before you start taking DYNAFLOC.
SCHEDULING STATUS: S4 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: DYNAFLOC 250 (tablets) DYNAFLOC 500 (tablets) DYNAFLOC 750 (tablets) Read this entire leaflet carefully before you start taking
More informationPackage leaflet: Information for the patient. Clarithromycin Kern Pharma 500 film-coated tablets Clarithromycin
Package leaflet: Information for the patient Clarithromycin Kern Pharma 500 film-coated tablets Clarithromycin Read all of this leaflet carefully before you start taking this medicine because it contains
More informationBERLITHION 600 mg Capsule, soft
PACKAGE LEAFLET: INFORMATION FOR THE USER BERLITHION 600 mg Capsule, soft ALPHA LIPOIC (THIOCTIC ACID) This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for
More informationLimitations of Use: Glumetza is not used for the treatment of type 1 diabetes or ketoacidosis (1).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.20 Subject: Glumetza Page: 1 of 5 Last Review Date: March 18, 2016 Glumetza Description Glumetza (extended-release
More informationPackage leaflet: Information for the User
Package leaflet: Information for the User Yaltormin SR 500mg Prolonged Release Tablets Yaltormin SR 750mg Prolonged Release Tablets Yaltormin SR 1000mg Prolonged Release Tablets Metformin Hydrochloride
More informationPackage leaflet: Information for the patient
Package leaflet: Information for the patient Xigduo 5 mg/850 mg film-coated tablets Xigduo 5 mg/1,000 mg film-coated tablets dapagliflozin/metformin hydrochloride Read all of this leaflet carefully before
More informationPackage leaflet: Information for the user. Entecavir Alvogen 0,5 mg filmomhulde tabletten Entecavir Alvogen 1 mg filmomhulde tabletten Entecavir
Package leaflet: Information for the user Entecavir Alvogen 0,5 mg filmomhulde tabletten Entecavir Alvogen 1 mg filmomhulde tabletten Entecavir Read all of this leaflet carefully before you start taking
More informationMEDICATION GUIDE XIGDUO XR (ZIG- DO- OH X- R) (dapagliflozin and metformin HCL extended-release) Tablets
XIGDUO XR (dapagliflozin and metformin HCl extended-release) tablets 5 MEDICATION GUIDE XIGDUO XR (ZIG- DO- OH X- R) (dapagliflozin and metformin HCL extended-release) Tablets What is the most important
More informationPackage leaflet: Information for the user
Package leaflet: Information for the user Irbesartan 75mg Film-coated Tablets Irbesartan 150mg Film-coated Tablets Irbesartan 300mg Film-coated Tablets irbesartan Read all of this leaflet carefully before
More informationPackage leaflet: Information for the patient Tranexamic acid 100 mg/ml Solution for Injection tranexamic acid
Package leaflet: Information for the patient Tranexamic acid 100 mg/ml Solution for Injection tranexamic acid Read all of this leaflet carefully before you are given this medicine because it contains important
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Metformin 850mg Tablets BP 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains Metformin Hydrochloride 850mg equivalent
More informationSUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET
SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET 1 SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT GLUCOPHAGE 850 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE
More informationIrbenida 150 mg film-coated tablets; 300 mg film-coated tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER Irbenida 150 mg film-coated tablets; 300 mg film-coated tablets IRBESARTAN This leaflet is a copy of the Summary of Product Characteristics and Patient Information
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT GLUCOPHAGE 1000 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One film-coated tablet contains 1000 mg metformin
More informationPackage leaflet: Information for the patient. Tranexamic Acid 100 mg/ml, Solution for Injection tranexamic acid
Package leaflet: Information for the patient Tranexamic Acid 100 mg/ml, Solution for Injection tranexamic acid Read all of this leaflet carefully before you are given this medicine because it contains
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. GLUCOPHAGE 1000 mg film-coated tablets metformin hydrochloride
PACKAGE LEAFLET: INFORMATION FOR THE USER GLUCOPHAGE 1000 mg film-coated tablets metfmin hydrochlide Read all of this leaflet carefully befe you start taking this medicine. - Keep this leaflet. You may
More informationPATIENT INFORMATION LEAFLET
MAGNEZINC Film Coated Tablets For oral use. PATIENT INFORMATION LEAFLET Active substance(s): Each film tablet contains 30 mg zinc equivalent to 82.6 mg zinc sulfate monohydrate and 300 mg magnesium equivalent
More informationNEW ZEALAND DATA SHEET. Each film coated tablet contains 500 mg, 850 mg or 1000 mg of metformin hydrochloride.
NEW ZEALAND DATA SHEET METFORMIN MYLAN 1. Product Name Metformin Mylan, 500 mg, 850 mg & 1000 mg, film coated tablet 2. Qualitative and Quantitative Composition Each film coated tablet contains 500 mg,
More informationNeuro-Medivitan is a vitamin preparation. Intended use Systemic neurological disorders due to proven deficiency of vitamins B1 and B6.
Unofficial translation of the German package leaflet Patient Information Leaflet: Information for users Neuro-Medivitan, film-coated tablets Active substances: thiamine chloride hydrochloride / pyridoxine
More informationMetoclopramide hydrochloride mg (Quantity corresponding to anhydrous metoclopramide hydrochloride) mg
Name Primperan 10 mg Breakable tablets Metoclopramide hydrochloride Before taking this medicine Carefully read the entirety of this leaflet before taking this medicine. It contains important information
More informationPackage leaflet: Information for the patient. Competact 15 mg/850 mg film-coated tablets pioglitazone/metformin hydrochloride
Package leaflet: Information for the patient Competact 15 mg/850 mg film-coated tablets pioglitazone/metformin hydrochloride Read all of this leaflet carefully before you start taking this medicine because
More informationZANOSAR 1g. STREPTOZOCINE Lyophilised powder for solution for injection
PACKAGE LEAFLET: INFORMATION FOR THE USER ZANOSAR 1g STREPTOZOCINE Lyophilised powder for solution for injection Read all of this leaflet carefully before you start using this medicine. Keep this leaflet.
More information1) Reduction of hepatic glucose production by inhibiting gluconeogenesis and glycogenolysis
Diabex Metformin hydrochloride PRODUCT INFORMATION Name of the Medicine Active ingredient: Chemical name: Metformin hydrochloride. 1,1-dimethylbiguanide hydrochloride. Structural formula: Molecular Formula:
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER Irbea 75 mg film-coated tablets Irbesartan
PACKAGE LEAFLET: INFORMATION FOR THE USER Irbea 75 mg film-coated tablets Irbesartan Read all of this leaflet carefully before you start taking this medicine because it contains important information for
More informationPackage leaflet: Information for the user. Dalmevin 50 mg tablets Vildagliptin
Package leaflet: Information for the user Dalmevin 50 mg tablets Vildagliptin Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
More informationTRANSPARENCY COMMITTEE OPINION. 29 April 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 April 2009 VELMETIA 50 mg/850 mg, film-coated tablets B/56 (CIP code: 386 778-0) VELMETIA 50 mg/1 000 mg, film-coated
More informationHave you seen a patient like Ronald *?
(linagliptin/metformin HCI) Have you seen a patient like Ronald *? *Hypothetical patient profile Ronald * : 70 years old Retired engineer *Hypothetical patient profile RONALD*: Metformin-uncontrolled T2D
More informationCa-C 1000 Calvive 1000 mg mg mg effervescent tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER Ca-C 1000 Calvive 1000 mg + 327 mg + 1000 mg effervescent tablets CALCIUM LACTATE GLUCONATE, CALCIUM CARBONATE, ASCORBIC ACID (VITAMIN C) This leaflet is a copy
More informationDialosa 1 mg, 2 mg, 3 mg, 4 mg and 6 mg tablets Glimepiride
PACKAGE LEAFLET: INFORMATION FOR THE USER Dialosa 1 mg, 2 mg, 3 mg, 4 mg and 6 mg tablets Glimepiride Read all of this leaflet carefully before you start using this medicine. - Keep this leaflet. You may
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Comfora 595 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One film-coated tablet contains: glucosamine sulphate
More informationPackage leaflet: Information for the patient. Janumet 50 mg/1,000 mg film-coated tablets sitagliptin/metformin hydrochloride
Package leaflet: Information for the patient Janumet 50 mg/1,000 mg film-coated tablets sitagliptin/metformin hydrochloride Read all of this leaflet carefully before you start taking this medicine because
More informationPackage leaflet: information for the user. Memantine STADA 20 mg filmomhulde tabletten. Memantine hydrochloride
Package leaflet: information for the user Memantine STADA 20 mg filmomhulde tabletten Memantine hydrochloride Read all of this leaflet carefully before you start taking this medicine because it contains
More information1) Reduction of hepatic glucose production by inhibiting gluconeogenesis and glycogenolysis
Diaformin Metformin hydrochloride PRODUCT INFORMATION Name of the Medicine Active ingredient: Chemical name: Metformin hydrochloride. 1,1-dimethylbiguanide hydrochloride. Structural formula: Molecular
More informationPATIENT INFORMATION. Metformin Hydrochloride Extended-Release Tablets USP (met-for-min HYE-droe-KLOR-ide)
PATIENT INFORMATION Metformin Hydrochloride Extended-Release Tablets USP (met-for-min HYE-droe-KLOR-ide) What is the most important information I should know about metformin hydrochloride extended-release
More informationMetformin AN tablets metformin (as hydrochloride)
Metformin AN tablets metformin (as hydrochloride) Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about. It does not contain all the available information.
More informationPATIENT INFORMATION Metformin Hydrochloride Extended-Release Tablets (met-for-min HYE-droe-KLOR-ide) Rx only
PATIENT INFORMATION Metformin Hydrochloride Extended-Release Tablets (met-for-min HYE-droe-KLOR-ide) Rx only What is the most important information I should know about metformin hydrochloride extended-release
More informationPRESCRIBING INFORMATION (PI)
PRESCRIBING INFORMATION (PI) BYDUREON (exenatide) 2MG POWDER AND SOLVENT FOR PROLONGED-RELEASE SUSPENSION FOR INJECTION BYETTA (exenatide) 5 MICROGRAMS AND 10 MICROGRAMS SOLUTION FOR INJECTION, PREFILLED
More informationRead all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Package leaflet: Information for the patient Megalac Hydrotalcite Chewable Tablets 500 mg Active substance: hydrotalcite Read all of this leaflet carefully before you start taking this medicine because
More informationPackage leaflet: Information for the user. Irprestan 150 mg film-coated tablets. Irprestan 300 mg film-coated tablets irbesartan
Package leaflet: Information for the user 75 mg film-coated tablets 150 mg film-coated tablets 300 mg film-coated tablets irbesartan Read all of this leaflet carefully before you start taking this medicine
More informationPackage leaflet: Information for the user. Cetiristad 10 mg film-coated tablets Cetirizine dihydrochloride
Package leaflet: Information for the user Cetiristad 10 mg film-coated tablets Cetirizine dihydrochloride Read all of this leaflet carefully before you start taking this medicine because it contains important
More informationPATIENT INFORMATION LEAFLET TEXAMER
SCHEDULING STATUS: S2 PROPRIETARY NAME AND DOSAGE FORM: film-coated tablets Read all of this leaflet carefully because it contains important information for you. is available without a doctor s prescription,
More information2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Summary of Product Characteristics 1. NAME OF THE MEDICINAL PRODUCT {To be completed nationally} 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 mg tablets: each tablet contains 1 mg granisetron (as hydrochloride).
More informationMetex XR. What is in this leaflet. Before you take it. What METEX XR is used for. metformin hydrochloride. Consumer Medicine Information
metformin hydrochloride Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about METEX XR. It does not contain all of the available information. It does not
More informationPackage leaflet: Information for the user. Sebivo 600 mg film-coated tablets Telbivudine
Package leaflet: Information for the user Sebivo 600 mg film-coated tablets Telbivudine Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationPACKAGE LEAFLET Package leaflet: Information for the user. Ranitidin Actavis 150 mg and 300 mg film-coated tablets. Ranitidine
PACKAGE LEAFLET Package leaflet: Information for the user Ranitidin Actavis 150 mg and 300 mg film-coated tablets Ranitidine Read all of this leaflet carefully, before you start taking this medicine because
More informationElements for a public summary
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology The prevalence of diabetes for all age-groups worldwide was estimated to be 2.8% in 2000 and 4.4% in 2030. The total number of
More informationPRODUCT INFORMATION. FORMET ASPEN 500 and FORMET ASPEN 850
PRODUCT INFORMATION FORMET ASPEN 500 and FORMET ASPEN 850 Life threatening lactic acidosis can occur due to accumulation of metformin. Risk factors include renal impairment, old age and the use of high
More informationRead this entire leaflet carefully before you start taking DYNA BEZAFIBRATE. If you have further questions, please ask your doctor or your pharmacist.
SCHEDULING STATUS: S3 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: DYNA BEZAFIBRATE 400 SR (slow release tablets) Read this entire leaflet carefully before you start taking DYNA BEZAFIBRATE. Keep
More informationOral and Injectable Non-insulin Antihyperglycemic Agents
Appendix 5: Diabetes Education and Medical Management in Adults with Diabetes Oral and Injectable Non-insulin s This directive will be implemented by RPhs, RNs or RDs who have been deemed authorized implementers.
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Cinfalair 4 mg chewable tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER Cinfalair 4 mg chewable tablets Read all of this leaflet carefully before your child starts taking this medicine. Keep this leaflet. You may need to read it again.
More informationBISOLVON Chesty Forte.
New Zealand Consumer Medicine Information BISOLVON Chesty Forte Tablets 8 mg Bromhexine hydrochloride What is in this leaflet This leaflet answers some common questions about BISOLVON Chesty Forte. It
More informationMetformin appears to be a useful therapeutic option for physicians wishing to use drug therapy to control blood glucose levels. 3
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Type 2 diabetes mellitus Rates of diabetes are increasing worldwide. The International Diabetes Federation predicts that the number
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. SALAGEN 5 mg film-coated tablets. Pilocarpine hydrochloride
PACKAGE LEAFLET: INFORMATION FOR THE USER SALAGEN 5 mg film-coated tablets Pilocarpine hydrochloride Read all of this leaflet carefully before you start taking this medicine. Keep this leaflet. You may
More informationPackage leaflet: Information for the user. Nocdurna 25 microgram oral lyophilisate Nocdurna 50 microgram oral lyophilisate.
Package leaflet: Information for the user Nocdurna 25 microgram oral lyophilisate Nocdurna 50 microgram oral lyophilisate desmopressin Read all of this leaflet carefully before you start taking this medicine
More informationMedication Guide SEGLUROMET (seg-lur-oh-met) (ertugliflozin and metformin hydrochloride) tablets, for oral use
Medication Guide SEGLUROMET (seg-lur-oh-met) (ertugliflozin and metformin hydrochloride) tablets, for oral use Read this Medication Guide carefully before you start taking SEGLUROMET and each time you
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Raloxifen STADA 60 mg film-coated tablets (raloxifene hydrochloride)
PACKAGE LEAFLET 1 PACKAGE LEAFLET: INFORMATION FOR THE USER Raloxifen STADA 60 mg film-coated tablets (raloxifene hydrochloride) Please read this information carefully before you start to take your medicine.
More informationPIL. ParaCet Flu 500 mg+250 mg/sachet Powder for oral solution paracetamol + ascorbic acid
PIL ParaCet Flu 500 mg+250 mg/sachet Powder for oral solution paracetamol + ascorbic acid Please, carefully read this PIL before you start using the medicine. This medicine is available without prescription,
More informationConsumer Medicine Information TOPICIL. Please read this leaflet carefully before you start using Topicil Capsules.
Clindamycin hydrochloride Capsules 150 mg What is in this leaflet Consumer Medicine Information TOPICIL Please read this leaflet carefully before you start using Topicil Capsules. This leaflet answers
More informationPRODUCT INFORMATION. FORMET 500 and FORMET 850 (Blister Packs) AUST R &
PRODUCT INFORMATION FORMET 500 and FORMET 850 (Blister Packs) AUST R 193136 & 193137 Life threatening lactic acidosis can occur due to accumulation of metformin. Risk factors include renal impairment,
More informationFORMET 500 (Bottle) AUST R Metformin hydrochloride
1 FORMET 500 (Bottle) AUST R 192236 Metformin hydrochloride PRODUCT INFORMATION Life threatening lactic acidosis can occur due to accumulation of metformin. Risk factors include renal impairment, old age
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Glucose Intravenous Infusion BP 10% w/v solution for infusion Glucose (as glucose monohydrate)
PACKAGE LEAFLET: INFORMATION FOR THE USER Glucose Intravenous Infusion BP 10% w/v solution for infusion Glucose (as glucose monohydrate) Read all of this leaflet carefully before you start using this medicine
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Colecalciferol Meda 800 IU tablet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains colecalciferol (vitamin D 3 ) 800 IU
More informationPRONUNCIATION: (met-for-min) COMMON BRAND NAME(S): Riomet
PRONUNCIATION: (met-for-min) COMMON BRAND NAME(S): Riomet HOW TO USE: Read the Patient Information Leaflet if available from your pharmacist before you start taking metformin and each time you get a refill.
More informationChemmart Metformin 500/850/1000 Contains the active ingredient metformin (met-for-min) hydrochloride
Contains the active ingredient metformin (met-for-min) hydrochloride Consumer Medicine Information For a copy of a large print leaflet, Ph: 1800 195 055 What is in this leaflet Read this leaflet carefully
More informationPATIENT INFORMATION LEAFLET FOR TEXA 10 mg TABLETS AND TEXA SYRUP PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM:
SCHEDULING STATUS: S2 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: TEXA 10 mg (tablets) TEXA SYRUP (syrup) Read this entire leaflet carefully before you start taking TEXA. Keep this leaflet. You
More informationPackage leaflet: Information for the patient. Risedronate sodium 35 mg film-coated tablets. Risedronate sodium
Package leaflet: Information for the patient Risedronate sodium 35 mg film-coated tablets Risedronate sodium Read all of this leaflet carefully before you start taking this medicine because it contains
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT SPASMAG, capsule 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Magnesium sulphate trihydrate... 423.5 mg quantity equivalent to elemental
More informationPackage leaflet: Information for the patient. Forxiga 5 mg film-coated tablets Forxiga 10 mg film-coated tablets dapagliflozin
Package leaflet: Information for the patient Forxiga 5 mg film-coated tablets Forxiga 10 mg film-coated tablets dapagliflozin Read all of this leaflet carefully before you start taking this medicine because
More informationRANIBOS 150mg Film-coated tablets; 300mg Film-coated tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER RANIBOS 150mg Film-coated tablets; 300mg Film-coated tablets RANITIDINE This leaflet is a copy of the Summary of Product Characteristics and Patient Information
More informationOnglyza CONSUMER MEDICINE INFORMATION
What is in this leaflet Onglyza Saxagliptin 2.5 mg and 5 mg film coated tablets CONSUMER MEDICINE INFORMATION This leaflet answers some of the common questions people ask about Onglyza. It does not contain
More informationPATIENT INFORMATION LEAFLET
PATIENT INFORMATION LEAFLET Page 1 of 8 PATIENT INFORMATION LEAFLET 300mg Tablets * tenofovir disoproxil fumarate Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet.
More information